Proinflammatory cytokines and polycystic ovary syndrome




polycystic ovary syndrome, interleukin-18, myeloperoxidase


Polycystic ovary syndrome (PCOS) is a common disease, with a detection rate from 6 to 20% depending on the used criteria. Today patients with obesity have been often diagnosed with PCOS, but also it diagnoses in women with normal body weight. So the population studies shows that between 30% and 70% of women with PCOS has a normal body weight. And if today find many of the mechanisms of its formation in patients who are overweight, the pathogenesis of PCOS in women with normal body weight at the present stage is completely unclear.

Research took part in 120 women with normal weight, who was diagnosed polycystic syndrome ovary on the basis of clinical practice guidelines of Endocrine Society USA (2013), of them 80 women with PCOS run on the background of pelvic inflammatory diseases (PID). Participants were comparable in age and body mass index.

Status of the system mediators inflammation studied on the determining level of interleukin-18 and myeloperoxidase in blood serum in first phase menstrual cycle.

An analysis of the average pro-inflammatory cytokines in the serum of women with normal body weight and PCOS, which occurs on the background of PID found elevated levels of interleukin-18 – 262.87 ± 40.57 pg/ml and myeloperoxidase – 63.29 ± 4.13 ng/ml.

A positive correlative relationship between the level of interleukin-18, and the index of free testosterone in women with PCOS on the background of PID (r = 0.7) (p < 0.05).

It can be assumed that the inflammatory diseases of the genitalia play an important role in the formation of the PCOS manifestations in women with normal body weight due to increased production of proinflammatory cytokine interleukin-18 and myeloperoxidase, which may be a prerequisite for circulatory disorders in ovarian, folliculogenesis processes and hormone production.

Author Biographies

Н. В. Косей, SI «Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine»

MD, Chief researcher at the Department of Endocrine Gynecology

З. Б. Хоминская, Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine

MD, professor, head of the endocrinology laboratory of with a biochemistry group

Г. В. Ветох, Consultation and Diagnostic Centre of Dnieper district of Kiev

Obstetrician-gynecologist at the Female consultation a branch number 3 

Е. И. Березовская, Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine

Junior research at the Endocrine Gynecology Department

Т. Ф. Татарчук, Institute of Pediatrics, Obstetrics and Gynecology of the NAM S of Ukraine

MD, professor, corresponding member of the NAMS of Ukraine, Deputy Director for Research Work, Chief of the Endocrine Gynecology Department


  1. Ehrmann, D. “Polycystic ovary syndrome.” New England Journal of Medicine, 352(2005).
  2. Kulagina, N.V., Efimenko, O.A. “Experience of treatment of polycystic ovary syndrome.” Reproductive Endocrinology, 2(4) (2012): 74–78.
  3. Katsikis, I., Karkanaki, A., Misichronis, G., et al. “Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome.” Eur J Obstet Gynecol Reprod Biol, 156(2011): 181–185.
  4. Balen, A.H., Conway, G.S., Kaltsas, G. “Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients.” Hum Reprod, 10(1995): 2107–2111.
  5. Kaya, C., Pabuccu, R., Berker, B., Satiroglu, H. “Plasma interleukin-18 levels are increased in the polycystic ovary syndrome: relationship of carotid intima-media wall thickness and cardiovascular risk factors.” Fertil Steril, 93(2010): 1200–1207.
  6. Escobar-Morreale, H.F., Botella-Carretero, J.I., et al. “Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: Relationship to insulin resistance and to obesity.” J Clin Endocrinol Metab, 89(2004): 806–811.
  7. Okamura, H., Tsutsui, H., Kashiwamura, S.-I., et al. “Interleukin-18: a novel cytokine that augments both innate and acquired immunity.” Adv Immunol, 70(1998): 281–312.
  8. Ribeiro, A.L., Scapinelli, A., Tamanaha, S., Oliveira, R.M., et al. “Myeloperoxidases and polycystic ovary syndrome.” Endocrinol, 1(2012): 3–6.
  9. Simbirtsev, A.S. “Cytokines – a new system of regulation of defense reactions.” Cytokines and Inflammation, (2002).
  10. Demyanov, A.V., Kotov, A.Y., Simbirtsev, A.S. “Diagnostic value of cytokine levels in clinical practice.” Cytokines and Inflammation, (2003).
  11. Novikov, D.K., Novikov, P.D. Clinical immunopathology. St. Petersburg. Medical Literature (2009): 464 p.
  12. Cataldo, N.A., Dumesic, D.A., Goldsmith, P.C., Jaffe, R.B. “Immunolocalization of Fas and Fas ligand in the ovaries of women with polycystic ovary syndrome: relationship to apoptosis.” Hum Reprod, 15(9) (2000): 1889–1897.
  13. Klebanoff, S.J. “Myeloperoxidase: friend and foe.” J Leukoc Biol, 77(5) (2005): 598–625.
  14. Vladimirov, Y.A. “Free radicals in biological systems.” Soros Educational Journal, 2(2000): 154–156.



How to Cite

Косей, Н. В., Хоминская, З. Б., Ветох, Г. В., Березовская, Е. И., & Татарчук, Т. Ф. (2015). Proinflammatory cytokines and polycystic ovary syndrome. REPRODUCTIVE ENDOCRINOLOGY, (25), 56–60.



Children gynecology